Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Status:
Unknown status
Trial end date:
2010-09-01
Target enrollment:
Participant gender:
Summary
To determine the activity of weekly Docetaxel and Gemcitabine in patients with advanced soft
tissue sarcoma previously treated with anthracycline and/or ifosfamide
1. Primary endpoint: response rate
2. Secondary endpoint: progress-free survival, overall survival, safety
Phase:
Phase 2
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Korea University Anam Hospital Samsung Medical Center Severance Hospital